Gross Profit: Revenues from operations less the associated costs.
Atrium Therapeutics, Inc. (RNA) had Gross Profit of 18.75M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
18.75M |
|
-684.63M |
|
-- |
|
|
Gross Profit |
18.75M |
205.54M |
|
-186.78M |
|
61.31M |
|
-684.63M |
|
-684.63M |
|
-684.63M |
|
-684.63M |
|
-684.63M |
|
-684.63M |
|
-186.78M |
|
-186.78M |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
1.80B |
|
23.33M |
|
23.33M |
|
1.96B |
|
195.45M |
|
-- |
|
-- |
|
269.45M |
|
-1.58B |
|
1.69B |
|
1.69B |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-995.92% |
|
-995.92% |
|
-995.92% |
|
-3650.39% |
|
-3650.39% |
|
-- |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
43.39% |
|
-40.54% |
|
-34.96% |
|
-40.54% |
|
-- |
|
-- |
|
-- |
|